written on 23.05.2014
Tags:
,

Amgen's Vectibix scores first-line approval in wild-KRAS colorectal cancer

TAGS: ,

The FDA has OK'd the use of Amgen's Vectibix as a first-line treatment for wild-type KRAS metastatic colorectal cancer. The agency approved the frontline use of the drug in combination with Folfox chemotherapy.

Latest Report